share_log

Aptevo Therapeutics Announces Advancements In Clinical Programs And One Preclinical Program

Benzinga ·  Apr 10 09:09
  • Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the potential for greater clinical benefit in theALG.APV-527clinical trial
    • Cohort 5 dosing imminent, trial more than 50% enrolled
  • APVO436Phase 1b/2 dose optimization trial initiation expected 1H 2024
    • Premier CRO, Prometrika, engaged as partner for dose optimization trial to evaluate APVO436 in frontline AML in combination with venetoclax + azacitidine in venetoclax naïve patients
  • APVO711demonstrates its ability to induce tumor killing properties in preclinical studies
    • APVO711 dual mechanism checkpoint inhibitor with unique precision targeting capabilities progressing...
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment